NHS Lothian, Edinburgh, UK.
NHS Lothian, Edinburgh, UK
BMJ Case Rep. 2024 May 6;17(5):e255407. doi: 10.1136/bcr-2023-255407.
Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous atrophy. Transiently raised anti-tissue transglutaminase (ATTG) antibody has also been rarely reported in the literature.We describe the case of a woman in her mid-50s, who presented with a history of intermittent loose stools over 1 year, associated with significant weight loss. She had two marginally raised serum ATTG antibody tests during her work-up.After extensive investigations, she was diagnosed with olmesartan-induced enteropathy. On subsequent follow-up, her symptoms had resolved with cessation of her olmesartan therapy.This case adds to existing literature, highlighting the importance of considering olmesartan as a possible differential diagnosis for SLE. It also reports the presence of a raised ATTG antibody which is infrequently reported in this context.
奥美沙坦是一种血管紧张素 II 受体阻滞剂，已获许可用于治疗高血压。它可引起类似乳糜泻的肠病（SLE），其特征为慢性腹泻、体重减轻和绒毛萎缩。文献中也罕见报道短暂性抗组织转谷氨酰胺酶（ATTG）抗体升高。我们描述了一位 50 多岁女性的病例，她因间歇性稀便就诊，病史超过 1 年，伴有明显体重减轻。在她的检查过程中，有两次血清 ATTG 抗体检测结果略高。经过广泛的检查，她被诊断为奥美沙坦引起的肠病。随后的随访中，她停止使用奥美沙坦治疗后症状已缓解。本病例增加了现有文献，强调了将奥美沙坦视为 SLE 可能鉴别诊断的重要性。它还报告了存在升高的 ATTG 抗体，在这种情况下很少有报道。
